4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,218,405 | -32.1% | 1,902,467 | -3.6% | 0.00% | 0.0% |
| Q2 2023 | $35,653,952 | +34.2% | 1,973,102 | +27.6% | 0.00% | 0.0% |
| Q1 2023 | $26,573,745 | -6.0% | 1,545,884 | +21.5% | 0.00% | 0.0% |
| Q4 2022 | $28,255,785 | +166.1% | 1,272,210 | -3.6% | 0.00% | – |
| Q3 2022 | $10,617,000 | +15.1% | 1,320,362 | -0.1% | 0.00% | – |
| Q2 2022 | $9,228,000 | -52.7% | 1,322,149 | +2.4% | 0.00% | – |
| Q1 2022 | $19,519,000 | -30.7% | 1,290,941 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $28,152,000 | +10.3% | 1,283,083 | +35.6% | 0.00% | 0.0% |
| Q3 2021 | $25,513,000 | +125.3% | 945,977 | +101.2% | 0.00% | – |
| Q2 2021 | $11,325,000 | -40.3% | 470,276 | +7.6% | 0.00% | -100.0% |
| Q1 2021 | $18,969,000 | +4481.9% | 437,262 | +4272.6% | 0.00% | – |
| Q4 2020 | $414,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |